geneTIGA
Hospitals And Health Care
Iga Nephropathy (igan)—the Most Common Glomerulonephritis and a Leading Cause of End-stage Renal Disease. This Therapy Could Also Provide a Blueprint for Tackling Other Diseases with Selective B-cell Pathogenesis
31 employees
- Employees
- 31
geneTIGA Overview
- Headquarters
- Iga Nephropathy (igan)—the Most Common Glomerulonephritis and a Leading Cause of End-stage Renal Disease. This Therapy Could Also Provide a Blueprint for Tackling Other Diseases with Selective B-cell Pathogenesis
- Website
- www.genetiga-horizon.eu
- Industry
- Hospitals And Health Care
- Employees
- 31
- NAICS
-
Health Care and Social AssistanceSocial Assistance
Keywords
About geneTIGA
A blueprint approach for safe & efficient genome editing of T cells to sustainably combat several immune diseases and cancers related to B-cell pathology
Compare Similar Companies to geneTIGA
Weill Cornell Medicine
Hospitals And Health Care
Centre for Human Genetics
Biotechnology Research
Institute for Medical Research and Occupational Health
Research Services
Institute for Innovation and Technology (iit)
Think Tanks
Swiss Biotech Association
Biotechnology Research
AID Autoimmun Diagnostika GmbH
Biotechnology
Innovation Acta S.r.l.
Business Consulting And Services
The DTU Alt Protein Project
Education
Quality in Organ Donation - QUOD
Research
QUANTUM TECHNOLOGIES LIMITED
Manufacturing